Next Generation Partners

Rising Stars

Biotechnology in East Anglia


Goodwin has 'an understanding of the biotech landscape, the pressures on biotech companies and the experience in biotech licensing deals globally'. Clients remark that one of its key strengths is its 'experienced associates who work autonomously, closely in communication with partners', resulting in a practice that is 'very responsive and able to provide creative proposals to address potential problems'. Among its clients are pharmaceutical company Teva and gene and cell therapy company Oxford Biomedica. The practice is led by life sciences and technology M&A and finance partner David Mardle, commercial IP specialist Malcolm Bates and licensing and contracts expert Tim Worden, who all work in both the Cambridge and London offices. Newly promoted counsel Talitha Shkopiak specializes in commercial agreements forthe creation and commercialisation of IP rights, notably for biotechnology companies.

Practice head(s):

Malcolm Bates; David Mardle; Tim Worden

Other key lawyers:

Talitha Shkopiak


‘Understanding of the biotech landscape, the pressures on biotech companies and experience on biotech licensing deals globally.’

‘Experienced associates that work autonomously, closely in communication with partners.’

‘Very responsive and able to provide creative proposals to address potential problems.’

‘Thorough and significant sector knowledge and experience.’

‘I had the opportunity to interact with two different lawyers at Goodwin and I have to say that the negotiation certainly improved thanks to the feedback received and the team style. I was provided with clear recommendations and/or clear consequences from accepting or not the recommendations in a way that the negotiation with the partner became much more intuitive and clear.’

‘They have gravitas and courage to actually help guiding the negotiation when needed.’

‘Extremely positive experience working with the Goodwin team on a pharma licensing transaction. Felt they really cared about the transaction and made themselves available day and night to meet very tight deal deadlines.’

‘Tim Worden is extremely knowledgeable and experienced on all aspects licensing transactions. A very calm but engaging personality. He is very good at highlighting and then resolving different challenges arising in a negotiation. I always have the impression nothing gets past Tim which gives me comfort we have the right lawyer representing us.’

Key clients


Oxford Biomedica

Calliditas Therapeutics

CMR Surgical


Orexia Therapeutics






Ellipses Pharma

Work highlights

  • Advised Teva Pharmaceutical Industries Ltd on a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
  • Advised Calliditas Therapeutics AB on a strategic licence agreement with STADA Arzneimittel AG to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area member states, Switzerland and the UK.
  • Advising Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.

Taylor Wessing LLP

The Cambridge office of Taylor Wessing LLP plays a key role in the firm's international biotechnology practice, which counts Cambridge Innovation Capital, Apollo Therapeutics and Illumina among its clients. Clients remarks upon 'a friendly practice with a pragmatic and solution-orientated approach, providing clear explanation of complex issues and the associated risks'. Its work spans corporate advice, litigation, venture capital funding and regulatory matters. Practice head Alison Dennis, who works in both Cambridge and London, advises international life sciences companies on EU regulations for medical devices and pharmaceuticals. Highly regarded IP lawyer Adrian Toutoungi, corporate partner Ross McNaughton and key partner Tasmina Goraya, who handles a broad range of regulatory and compliance issues relating to pharmaceuticals, medical devices, food supplements, human cells and tissue, play pivotal roles in the practice.

Practice head(s):

Alison Dennis

Other key lawyers:

Adrian Toutoungi; Tasmina Goraya; Ross McNaughton


‘A friendly practice with a pragmatic and solution-orientated approach, providing clear explanation of complex issues and the associated risks.’

‘A strength of Taylor Wessing is the depth of knowledge and expertise across different legal areas, and we were able to access this on a particularly complex transaction under the truly excellent leadership of Ross McNaughton.’

‘Partner responsiveness, competitive costs and quality of team lead us to engage the firm regularly.’

‘Ross McNaughton and Adrian Toutoungi are our go-to partner specialists.’

‘Very strong sector expertise. Adaptive to small start-ups.’

‘The team consistently delivers work of a top quality, in a timely fashion and are very pleasant to work with.’

Key clients

Adrestia Therapeutics

Apollo Therapeutics


Cambridge Enterprise

Cambridge Epigenetix

Cambridge Innovation Capital

Cell and Gene Therapy Catapult


Drishti Discoveries



Fusion Antibodies


ImmTune Therapeutics


Mission Therapeutics

My Personal Therapeutics

Nuclera Nucleics


Reflection Therapeutics




Start Codon cohort companies

TranSINE Therapeutics


Work highlights

  • For Centessa Pharmaceuticals, the firm acted on the transformational roll-up and $250 million crossover financing for a number of cutting-edge UK and European biotech companies.
  • Advised fast-growing biotech company, Nuclera, on its acquisition of E Ink’s digital microfluidics unit.
  • Advised Cambridge Epigenetix on its $88 million Series D financing led by Temasek to advance its best-in-class DNA sequencing technology platform.

Mills & Reeve LLP

The Cambridge office of Mills & Reeve LLP is 'pragmatic and provides good all round advice on agreements, fund-raising and due diligence'. The firm has a large multidisciplinary team that acts for global companies, among them GlaxoSmithKline, as well as universities and early-stage biotechnology companies. It is also a leading adviser to research institutes and medical research charities. Its work spans corporate transactions, IP, regulatory advice, HR issues and disputes. Practice head James Fry (who has 'excellent oversight of what is need to support a growing biotech company') advises life sciences companies on intellectual property matters and complex commercial contracting. Fund creation specialist Dona Ardeman , corporate partner Jonathan Greenwood , employment adviser Melanie James and corporate finance expert Zickie Lim  are among the partners who play central roles in the biotechnology practice.

Practice head(s):

James Fry

Other key lawyers:

Dona Ardeman; Jonathan Greenwood; Melanie James; Zickie Lim; James Edmonds


‘Pragmatic, good all round advice – from agreements, fund-raising and due diligence.’

‘James Fry has excellent oversight of what is need to support a growing biotech company.’

‘The M&R Team that we interact with feel like an extension of our business. They are extremely responsive and a pleasure to work with. The M&R team work with us on a variety of different areas across our business: corporate, regulatory, employment, commercial.. and do a great job in all areas.’

‘James Fry and associate James Edmonds are my main contacts and both do a fantastic job.’

‘Experts in their field with a pragmatic approach.’

‘James Fry provides guidance like a General Counsel.’

‘Mel James is first class. Her advice is clear, practical and she is a great support on potentially contentious employment matters.’

Key clients

F-star Therapeutics


The Binding Site

Mission Therapeutics

Autolus Limited

Kadans Science Partners

Diurnal Group

Charnwood Molecular Limited

Sphere Fluidics

Redx Pharma

Work highlights

  • Acted for long standing client, F-star Therapeutics, on its licence and collaboration agreement with Janssen Biotech, Inc.
  • Provided full-service advice to Autolus in relation to the agreement and a 20 year lease to be granted following completion of the works, along with advising in relation to construction matters.
  • Advised on the sale of the entire issued share capital of molecular diagnostics company Biocrucible Limited to KKR Sapphiros LP (“Sapphiros”). Sapphiros has been established by KKR and Namal Nawana to invest in growth-stage companies offering sophisticated near-patient diagnostic technologies. The transaction also involved the spin out of Biofaze Limited, to develop a range of new therapeutic applications. Mills & Reeve have acted for Biocrucible since it was a start-up company.

Penningtons Manches Cooper LLP

The team Penningtons Manches Cooper LLP acts for a wide range of clients across the therapeutics, medical devices, agricultural and veterinary fields. It counts medical research charity Parkinson’s UK, component supplier for protein structure determination by X-ray crystallography Molecular Dimensions, and clinical biopharmaceutical company SynOx Therapeutics among its clients. The firm's work encompasses corporate transactions, financing, IP, real estate and employment matters. IP, IT and commercial partner Rachel Bradley in Cambridge, who has a particular specialism in the life sciences and publishing sectors, is co-head of a five-partner, cross-office practice. 'She understood our requirements and provided an appropriate level of review and advice without over complicating matters', remarks one client. Employment partner Hilary Aldred is a key member of the practice.

Practice head(s):

Rachel Bradley

Other key lawyers:

Hilary Aldred


‘The firm understands the sector and the requirements of firms like ours.’

‘Rachel Bradley understood our requirements and provided an appropriate level of review and advice without over complicating matters.’

‘Rachel Bradley has been very responsive, rapid and transparent, and understands our broader business context and advises appropriately.’

Key clients

The Company of Biologists Limited

Parkinson’s UK

Applied Molecular Transport, Inc

Vivifi Biotech Ltd

Fluid Pharma Ltd

Royal National Orthopaedic Hospital

Enterprise Therapeutics

Metrion Biosciences

Abcam PLC

King’s College London

Synox Therapeutics

MitoRx Therapeutics Limited

42 Technology Limited

Oxford Cannabinoid Technologies

Molecular Dimensions

Certis Europe B.V.

Birch Tree IP

Work highlights

  • Advising Oxford Cannabinoid Technologies on the company’s IPO on the London Stock Exchange, and on all IP and Commercial aspects of the IPO.
  • Supported Fluid Pharma with reviewing its funding agreement with Unitaid for a grant to develop novel paediatric medicines for malaria using Fluid Pharma’s MicroCoat™ technology, and drafted collaboration agreements for Fluid to use with some of its partners for the project, which had to be consistent with key provisions of the main funding agreement.
  • Acting as lead co-ordinator of the review of all European clinical trial agreements for Applied Molecular Transport, Inc, for trials to occur in sites across numerous countries in Europe.